Immune to Cancer: The CRI Blog
-
CRI Funded Scientist
Laura Mackay, PhD
T cells are central to controlling cancer, and immunotherapies that activate them have transformed treatment over the… -
CRI Funded Scientist
Yubin Kang, MD
CAR T-cell therapy has revolutionized treatment for blood cancers like multiple myeloma by engineering a patient’s own… -
CRI Funded Scientist
Michael Curran, PhD
Unlike normal cells, which grow in a controlled and orderly fashion, tumors grow rapidly and chaotically. To… -
CRI Funded Scientist
Sidi Chen, PhD
CAR T-cell therapy has revolutionized blood cancer treatment, but it hasn’t yet cracked the code for solid… -
CRI Funded Scientist
Peiwen Chen, PhD
Glioblastoma (GBM) is one of the most aggressive, treatment-resistant cancers and has seen little improvement in patient… -
CRI Funded Scientist
David Braun, MD, PhD
Immune checkpoint inhibitors are a common treatment for solid tumors, but for many patients, these drugs don’t… -
CRI Funded Scientist
Anna Ralser, MD, PhD
Colorectal cancer (CRC) remains a leading cause of cancer deaths and is largely unresponsive to immunotherapy due… -
CRI Funded Scientist
Rajat Punia, PhD
Hepatitis C virus (HCV) is a leading cause of liver cancer and responsible for nearly 300,000 deaths… -
CRI Funded Scientist
Maryam Pourmaleki, PhD
Colorectal cancer (CRC) is a leading cause of cancer-related death, with most mortality driven by metastasis –…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.